Warfarin sodium
Questions
| Reviews 
Warfarin monitoring tests
It's important to monitor PT and INR with warfarin, but the question is: Do we need to monitor "platelet" and/or "ESR" with warfarin therapy as well? Which is the most important out of these two parameters to monitor?
by Hany Khalil, 10/25/2006
correct dosage of warrarin sodium
Doctor would like my INR at 1.5. It is at 2.9 right now. My Warfarin sodium is alternating 3. & 3.5. should my dosage of warfarin go up or down.
by Joe Keller in Chatham Ontario Canada, 07/06/2006
Warfarin information
I am going off warfarin for a week to have a biopsy done. How many days will it take for the warfarin to be fully effective once I begin the drug again? I suffer from DVT's and need to begin airplane travel again following the procedure.
by Rusty in Orange Co., CA, 03/16/2006
Procreation; any effects to males?
Does taking Warfarin have any impact on male potency? I'm taking 5 to 7.5 mgs daily. A pacemaker was inserted on Januray 24, 2006. PT level is around 2.1 - 2.3. I am taking no other medication. I am not allergic to anything, that I know of. I am funct...
by Anonymous in Ft. Pierce, Florida, 03/15/2006
WARFARIN SODIUM 5 MG TABLET
I have been taking this med for 2½ months to treat blood clots in my right leg do to injury of my MCL in early December of 2005. I have had no side effects until about three weeks ago. Thats when my left hand (primarily the knuckels) on the middle th...
by Carl G in Cleveland, Ohio, 03/06/2006
|
Classification: Anticoagulant Action/Kinetics: Interferes with synthesis of vitamin K-dependent clotting factors resulting in depletion of clotting factors II, VII, IX, and X. Has no direct effect on an established thrombus although therapy may prevent further extension of a formed clot as well as secondary thromboembolic problems. Well absorbed from the GI tract although food affects the rate (but not the extent) of absorption. Suitable for parenteral administration. Peak activity: 1.5-3 days; duration: 2-5 days. t 1/2: 1-2.5 days. Highly bound to plasma proteins. Metabolized in the liver and inactive metabolites are excreted through the urine and feces. Uses: Prophylaxis and treatment of venous thrombosis and its extension. Prophylaxis and treatment of atrial fibrillation with embolization. Prophylaxis and treatment of pulmonary embolism. Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation. Investigational: Adjunct to treat small cell carcinoma of the lung with chemotherapy and radiation. Prophylaxis of recurrent transient ischemic attacks and to reduce the risk of recurrent MI. In combination with aspirin to reduce risk of a second MI. Contraindications: Lactation. IM use. Use of a large loading dose (30 mg) is not recommended due to increased risk of hemorrhage and lack of more rapid protection. Special Concerns: Geriatric clients may be more sensitive. Anticoagulant use in the following clients leads to increased risk: trauma, infection, renal insufficiency, sprue, vitamin K deficiency, severe to moderate hypertension, polycythemia vera, severe allergic disorders, vasculitis, indwelling catheters, severe diabetes, anaphylactic disorders, surgery or trauma resulting in large exposed raw surfaces. Use with caution in impaired hepatic and renal function. Safety and efficacy have not been determined in children less than 18 years of age. Careful monitoring and dosage regulation are required during dentistry and surgery. Side Effects: CV: Hemorrhage is the main side effect and may occur from any tissue or organ. Symptoms of hemorrhage include headache, paralysis; pain in the joints, abdomen, or chest; difficulty in breathing or swallowing; SOB, unexplained swelling or shock. GI: N&V;, diarrhea, sore mouth, mouth ulcers, anorexia, abdominal cramping, paralytic ileus, intestinal obstruction (due to intramural or submucosal hemorrhage). Hepatic: Hepatotoxicity, cholestatic jaundice. Dermatologic: Dermatitis, exfoliative dermatitis, urticaria, alopecia, necrosis or gangrene of the skin and other tissues (due to protein C deficiency). Miscellaneous: Pyrexia, red-orange urine, priapism, leukopenia, systemic cholesterol microembolization (``purple toes'' syndrome), hypersensitivity reactions, compressive neuropathy secondary to hemorrhage adjacent to a nerve (rare).
Laboratory Test Alterations:
False
Overdose Management: Symptoms: Early symptoms include melena, petechiae, microscopic hematuria, oozing from superficial injuries (e.g., nicks from shaving, excessive bruising, bleeding from gums after teeth brushing), excessive menstrual bleeding. Treatment: Discontinue therapy. Administer oral or parenteral phytonadione (e.g., 2.5-10 mg PO or 5-25 mg parenterally). In emergency situations, 200-250 mL fresh frozen plasma or commercial factor IX complex. Fresh whole blood may be needed in clients unresponsive to phytonadione.
Drug Interactions:
Warfarin is responsible for more adverse drug interactions than any other group. Clients on anticoagulant therapy must be monitored carefully each time a drug is added or withdrawn. Monitoring usually involves determination of PT or INR. In general, a lengthened PT or INR means potentiation of the anticoagulant. Since potentiation may mean hemorrhages, a lengthened PT or INR warrants
reduction of the dosage of the anticoagulant.However, the anticoagulant dosage must again be increased when the second drug is discontinued. A shortened PT or INR means inhibition of the anticoagulant and may require an increase in dosage.
How Supplied: Powder for injection: 5 mg; Tablet: 1 mg, 2 mg, 2.5 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg
Dosage
|
levels of serum theophylline determined by Schack and Waxler UV method (warfarin and dicumarol). Metabolites of indanedione derivatives may color alkaline urine red; color disappears upon acidification.
Anticoagulant effect
1 comment | Reply